<DOC>
	<DOCNO>NCT01125358</DOCNO>
	<brief_summary>This study design compare 3 dos LY2140023 treatment schizophrenia assess endpoint ( 7 week ) use Clinical Utility Index ( CUI ) , measure efficacy , safety , tolerability .</brief_summary>
	<brief_title>A Study Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Diagnosis schizophrenia define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ; APA 2000 ) ( Disorganized , 295.10 ; Catatonic , 295.20 ; Paranoid 295.30 ; Undifferentiated , 295.90 ) confirm Structured Clinical Interview DSMIVTR ( SCID ) Non pregnant female patient agree use acceptable birth control At entry study must consider moderately ill opinion investigator 1 year history Schizophrenia prior enter study At study entry patient history antipsychotic treatment must lifetime history least one hospitalization treatment schizophrenia , include hospitalization require study base investigator 's clinical judgment . Patients never take antipsychotic treatment may enter study even without history hospitalization At study entry patient history antipsychotic treatment must history least one episode illness exacerbation require intensification treatment intervention care last 2 year , include present episode illness . Patients never take antipsychotic treatment may enter study without past history illness exacerbation intensification treatment last 2 year At study entry patient must experience exacerbation illness within 4 week prior enter study , lead intensification psychiatric care opinion investigator . If exacerbation occur patient presently hospitalize , patient must hospitalize longer 60 day entry study Participated clinical trial pharmacological treatment intervention receive studyrelated medication 6 month prior visit 1 Previously complete withdrawn study , study investigate LY2140023 predecessor molecule glutamatergic activity Have know history receive treatment clozapine dose , determine baseline Have receive treatment depot formulation antipsychotic medication within 6 month prior enter study Patients currently suicidal Females pregnant , nursing , intend become pregnant within 30 day complete study Patients uncorrected narrowangle glaucoma , uncontrolled diabetes , certain disease liver , renal insufficiency , untreated thyroid condition serious unstable illness Have history one seizures , except experienced single simple febrile seizure age 6 month 5 year Patients exclude , biological father , mother , brother , sister , child history idiopathic epilepsy Within 1 year study enrollment , patient history central nervous system infection , uncontrolled migraine , transient ischemic attack ( TIA ) , head trauma loss consciousness postconcussive Patients exclude lifetime history following : head trauma , stroke , central nervous system ( CNS ) infection persistent neurological deficit ( focal diffuse ) ; brain surgery ; electroencephalogram paroxysmal ( epileptiform ) activity , brain structural lesion , include developmental abnormality , determine examination previous neuroimaging study consistent diagnosable neurological disease syndrome Electroconvulsive therapy ( ECT ) within 3 month enter study ECT time study Leukopenia Medical history Human Immunodeficiency Virus positive ( HIV+ ) status Higher normal blood prolactin level Certain electrocardiogram result</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>